Psychosocial and Relationship Issues in Men With Erectile Dysfunction

Functional Effects

Not being able to physically achieve or maintain an erection is important to the male and his sense of maleness. In the hierarchy of signs that confirm and confer manhood that correspond to sexual activity, men list having an erection at the top of their list, followed by penile penetration, sexual desire, and lastly, the ability to ejaculate (Pontin, Porter, & McDonagh, 2002). The inability to function sexually can impact the role a man plays in the world, thus taking away his identity. Therefore, the loss of erectile capability can have a profound effect on a man and how he is viewed by society (Dunsmuir, 1999). The ability to perform sexually is very important to a man. ED, resulting in the loss of sexual function, can lead to feelings of dissatisfaction with life and add to his stress (Jack, 2005).  Printer- Friendly Email This

Urol Nurs.  2006;26(6):442-446.  ©2006 Society of Urologic Nurses and Associates
This is a part of article Psychosocial and Relationship Issues in Men With Erectile Dysfunction Taken from "Price Compare Tadalafil" Information Blog

Are We Prepared? Interviews With Leading Experts

Are We Prepared? Interviews With Leading Experts

from Medscape Infectious Diseases

Preparing for a Smallpox Attack

Medscape: The current plans in the United States for an attack with smallpox is "ring vaccination" (surveillance containment). Do you think this approach is the best for the United States? Is the ring strategy better than the Israeli plan to vaccinate everyone?

Dr. Foster: There are 3 options — surveillance containment of first responders, voluntary vaccination, and compulsory vaccination. Given that there are types of smallpox that might miss detection in the first 48 hours (early disease or hemorrhagic smallpox), vaccination of first responders would provide protection to health workers seeing the first few cases. Given the risk of vaccination, surveillance containment is the appropriate strategy for community protection.

Dr. Kaplan: I think the ring strategy is flawed in several ways. The argument is whether one should vaccinate just the right people (ring strategy) vs trying to protect everyone as quickly as possible (post-attack mass vaccination). Rather than devoting scarce resources to tracing, locating, and vaccinating what seem to be exactly the "right" people, it is much more efficient in all but the smallest of attacks to mass vaccinate and bring the population to herd immunity levels as rapidly as possible. This is what the Israelis would do, either post-attack or pre-attack if intelligence estimates suggest a high enough likelihood of attack, and I think it is a much wiser approach to the control of smallpox in today's situation where, unlike the countries of the WHO eradication campaign, we have next to no immunity in the population, people are very mobile, and terrorists are presumably trying to kill us.

Dr. Lutwick: Ring immunization, which worked well in eradication of natural smallpox, is not likely to be effective. If smallpox were effectively introduced into a large cohort of susceptibles, a large outbreak would no doubt result. Universal or at least widespread immunization might blunt this. It would be reasonable to immunize a cohort of individuals who, based on their employment, would likely be at risk for smallpox. This may assist in blunting the outbreak, but will not help those not in this cohort.

Medscape: What about the risks of the current smallpox vaccine, and the liability for adverse effects?

Dr. Temte: On one hand, there's an undefined threat, and on the other, we have a vaccine that has pretty unacceptable adverse effects. When we start talking about immunizing entire populations, I get very worried, especially about liability. I have patients who will not get their children immunized against measles because of the mythical fear of autism. We've changed our polio vaccine because of the very, very rare case of induced polio from the oral vaccine, around 8 to 10 cases a year. With smallpox vaccine, for example, 70% of kids might get a high fever that lasts 14 days. I don't want to be the physician dealing with the parent of the child who gets the fever and can't go to day care, the parent misses work, etc. Those are the grim realities in primary practice.

Dr. Zelicoff: Given the ACIP's [Advisory Committee on Immunization Practices] instructions and assumptions (primarily, that the risk of smallpox was "low" but not quantified), they made the right choice, simply because the existing vaccine is so damned problematic. There is no question that if we were to engage in mass vaccination, hundreds to thousands of people in the United States would die or be severely sickened because they are immunocompromised; the vaccine is a live virus ("vaccinia") which was known to cause terrible problems even 50 years ago, before we had 10% of the population immunosuppressed at any given time.

Dr. Lutwick: Estimates of deaths associated with widespread reintroduction of the smallpox vaccine have been in the range of 300. These numbers, however, are based on risks of complications of a vaccine in a population from more than 3 decades ago. There are quite a lot more immunocompromised people wandering around now than there were then (HIV, chemotherapy, organ transplants, etc). Even if you were able to avoid directly immunizing any known immunocompromised individual, there are lots of HIV+ people who do not know it and, more importantly, secondary spread of vaccinia virus from a healthy vaccinee to an immune-suppressed contact or a patient with eczema (eczema vaccinatum) will likely be more common than before and hike up the numbers related to morbidity and mortality from the vaccine.

Once deaths of "innocent" people start to occur from any vaccinia program, given the environment we live in, the clamoring for smallpox vaccination may end quickly unless the disease breaks out. In this regard, it is my understanding that the Vaccination Protection Against Litigation legislation does not cover smallpox vaccine. I am not sure what protection will be offered to whatever company was involved in making the old vaccine, and if that occurs, who is left to be sued but the poor docs who immunize the patients who get or die from vaccinia complications?

Medscape: What other options do we have?

Dr. Zelicoff: What the Committee did not say (it wasn't required to) is that our work does not stop with the acquisition of 300 million doses of vaccine (due, by the way, on or about January 2003). Rather, we must continue to develop both a new vaccine and antiviral drugs. In other words, we need a better set of choices than the sole option we currently have.

Dr. Lutwick: The development of more modern smallpox vaccines that could have substantially less "toxicity baggage" may obviate much of the debate about immunization. Besides a standard tissue culture product, DNA (genomic), oral transgenic plant, or idiotype-anti-idiotype vaccines might be even better immunologically tailored immunogens.

It has always been my concern that epidemic, significant human poxvirus infection would return. Even if BT smallpox or even accidental release of nonBT virus was a nonissue, I have always thought that other similar orthopox viruses such as monkeypox or "white" pox — given the right mutation or other genetic recombination — would eventually cause these agents to become more infectious and virulent in humans.

Medscape: What about reports of successful aerosolization of smallpox by the Russians in 1971?

Dr. Zelicoff: The possibility of aerosolizing variola (smallpox) and disseminating it for 10 miles (or more) has long been discounted by experts. Thus, instead of the initial tranche of smallpox cases being in the 10s or 20s, as most of the models have assumed, now we have the possibility of hundreds, or more likely thousands of victims should smallpox ever be utilized as a biological weapon. Heaven help us then, because the strategy we have adopted (vaccinate a few first responders now, and the population at large only in the case of an attack) will collapse if smallpox is introduced as an aerosol.

Dr. Lutwick: It was suggested that the 1971 Aralsk USSR outbreak that was recently revealed (by Zelicoff and colleagues) was related to aerosolization of a plume of smallpox virus from the notorious island of Vozrozhdeniye, where lots of BT testing was done (Tucker JB, Zilinskas RA, eds. CNS Occasional Papers: #9: The 1971 Smallpox Epidemic in Aralsk, Kazakhstan, and the Soviet Biological Warfare Program. Available at http://cns.miis.edu/pubs/opapers/op9/index.htm). If that is the case, the virus was "hardened" (figuratively) to make it resistant to sunlight/UV inactivation. Even if that is true, I do not think it really matters, as even this strain required more classic person-to-person spread; a multicentric outbreak from bioterrorism through multiple geographically separate introductions (as might occur with "smallpox suicide bombers" — fanatics who are inoculated with smallpox and show up in a variety of locales late in their incubation periods) would produce a similar, albeit slower outbreak.

This is a part of article Are We Prepared? Interviews With Leading Experts Taken from "Ciprofloxacin (Generic Cipro) 500 mg" Information Blog

Eplerenone vs. Losartan in Low-Renin Hypertension Patients

Results

Patient Demographics and Disposition

A total of 168 patients were randomized to treatment by 26 investigators in 4 countries. Of these, 86 were treated with eplerenone and 82 received losartan, which provided 88% power to detect a 3.5-mm Hg difference in seated diastolic blood pressure. The characteristics of the patient groups were similar at baseline ( Table I ).

Mean seated blood pressures at baseline were similar in the eplerenone and losartan groups ( Table I ). Baseline geometric mean active plasma renin values also were similar in both groups (P = .408). The group mean values of the baseline active plasma renin levels <7.6 pg/mL (<13 mU/L) in both treatment groups confirm that the population met the protocol-specified definition of low-renin hypertension. The disposition of the patients during the conduct of the study is shown in Figure 2.

Figure 2.  (click image to zoom)

Patient disposition.      

Blood Pressure Effects

At the week 8 end point, the mean change from baseline in systolic blood pressure in the eplerenone group was significantly greater than in the losartan group (−15.8 ± 1.70 and −10.1 ± 1.70 mm Hg, respectively; P = .017) (Figure 3). The adjusted mean change from baseline in diastolic blood pressure after 8 weeks was −9.3 ± 0.96 mm Hg in the eplerenone group and −6.7 ± 0.96 mm Hg in the losartan group, P = .05 (Figure 3).

Figure 3.  (click image to zoom)

Adjusted mean change from baseline in diastolic and systolic blood pressure at weeks 8 and 16. *Noninferiority of eplerenone to losartan was established at both time points (P < .001). †P = .017 versus losartan. ‡P = .05 versus losartan. DBP, diastolic blood pressure; SBP, systolic blood pressure.      

At the week 16 end point, 40 patients in the eplerenone group and 25 patients in the losartan group remained at the initial study medication doses of 100 mg of eplerenone and 50 mg of losartan daily, respectively. A total of 23 patients were at the second dose level at the end of the study, either receiving eplerenone 200 mg (n = 12) or losartan 100 mg (n = 11). A greater proportion of patients in the losartan group than in the eplerenone group required additional therapy with hydrochlorothiazide at week 8 (42.0% vs 22.5%) and at week 16 (55.6% vs 32.5%; P = .003 for eplerenone vs losartan log-rank test) ( Table II ). Comparable antihypertensive effects were seen for the 2 study drugs by week 16, after hydrochlorothiazide was added to achieve blood pressure control.

The systolic blood pressure response according to the baseline active renin level was examined according to tertiles of active renin: <5.5 pg/mL (9.4 mU/L), 5.5 to 8.7 pg/mL (9.4-14.8 mU/L), and >8.7 pg/mL (14.8 mU/L). Eplerenone was consistently effective in lowering systolic blood pressure regardless of baseline renin level. Losartan response was associated with renin levels; specifically, patients with higher baseline renin levels had the greatest reduction in systolic blood pressure. In contrast, patients with lower baseline renin levels had greater systolic blood pressure reductions with eplerenone than with losartan (P < .015 in the lowest tertile) (Figure 4).

Figure 4.  (click image to zoom)

Mean change in systolic blood pressure by tertile of baseline active renin at week 8 (monotherapy). Asterisk indicates P = .015 versus losartan. Dagger, P = .067 versus losartan.      

Renin-aldosterone Responses

Active renin levels increased in both groups, with a greater increase in the losartan group, which was not significantly different from the eplerenone-treated group at week 8 (P = .416) and week 16 (P = .635) (Figure 5). As expected, in the eplerenone group, there were significant increases from baseline in serum aldosterone at the week 8 and 16 end points (P < .001). Increases in aldosterone levels were dose dependent, suggesting that increasing the eplerenone dose, along with adding hydrochlorothiazide, contributed to the enhanced blood pressure reductions observed at the week 16 end point. Within the losartan group, there was a significant reduction of aldosterone by week 8; however, by week 16, the reduction was no longer statistically significant. Regression analysis showed no association between baseline plasma active renin, serum aldosterone, or aldosterone/renin ratios and change in diastolic blood pressure within either treatment group.

Figure 5.  (click image to zoom)

Percent change from baseline in active renin and serum aldosterone levels at weeks 8 and 16. Asterisk indicates P ≤ .01 versus losartan. Dagger, after hydrochlorothiazide add-on therapy was permitted.      

Safety and Tolerability

Most patients in each group were exposed to the study drugs for at least 3 months (eplerenone 78%, losartan 82%). Treatment-emergent adverse events were reported by 62.8% (54/86) of patients in the eplerenone group and by 72.0% (59/82) of patients in the losartan group. There were no differences in adverse events among treatments, and most treatment-emergent adverse events were mild or moderate in severity. The adverse events that occurred in more than 5% of both eplerenone and losartan-treated patients were headache, upper respiratory tract infection, and dizziness. No single adverse event was reported significantly more frequently in either treatment group. No deaths occurred in either group. Adverse events considered serious were reported in 3 eplerenone patients (hyperparathyroidism, angina, and abnormal thinking) and 1 losartan patient (noncardiac chest pain); none of these events were attributed to the study medication by site investigators. There were 2 reports of gynecomastia and 1 of impotence in eplerenone-treated men. One event of impotence was reported in a losartan-treated male patient, and 2 events of menstrual disorder were reported in losartan-treated female patients. There was one eplerenone-treated patient (100-mg group) who had a transiently elevated potassium level (5.7 mEq/L at week 14 and 4.1 mEq/L at week 16). Thus, it is unclear whether this was due to the hemolysis or the study drug.  Printer- Friendly Email This

Am Heart J.  2005;150(3):423-433.  ©2005 Mosby, Inc.
This is a part of article Eplerenone vs. Losartan in Low-Renin Hypertension Patients Taken from "Price Compare Tadalafil" Information Blog

Latest news: 261 new galleries clip added at galleries blog.

Latest news: 261 new galleries clip added at free black pussy videos blog. Must visit!

Cotrimoxazole tended to confer

Fluoroquinolones were the only social class of antimicrobial drugs
associated with MRSA colonization and corruption.
AHRs were 2.57 and 2.49, respectively, presumably as a effect of their
hoo-ha of the patient’s construction microbiological plant life, the
selective abstinence of susceptible strains, and the gain in bacterial
bond with public knowledge fibronectin book binding proteins after
picture to ciprofloxacin. Given the nearly identical AHRs for the
social activity between fluoroquinolones and MRSA colonization and
corruptness, the latter was not likely due to confounding by data point
(e.g., clinicians who initiated ciprofloxacin as empirical direction
for nosocomial unhealthiness ultimately found to be caused by MRSA).
Cotrimoxazole tended to confer covering against MRSA, in understanding
with a recent composition screening that cotrimoxazole (buy bactrim online)
prophylaxis reduces the frequency of community-acquired MRSA among
HIV-infected adults. Aminoglycosides were not associated with CDAD,
MSSA, or MRSA.
This is a part of article Cotrimoxazole tended to confer Taken from "Ciprofloxacin (Generic Cipro) 500 mg" Information Blog

Treatment of Uncomplicated Cystitis in Women

Commentary

One hundred assemblage ago, mortal cystitis was not perceived by physicians to be such a big job.
Patients did suffer, but if they had no complicating factors and did not develop an stimulant geographic area ill health or sepsis, they eventually recovered (despite physicians’ ministrations), and frequent recurrences seemed to be rare.1 With the school text of antibiotics, it was firmly believed that UTIs would become a historical footnote.2 Sulfanilamide, introduced in 1937, was an effective care for acute cystitis, and ushered in the era of antimicrobial therapy for UTIs.
Side effects and bacterial mechanical phenomenon, however, restricted its usefulness and eventually that of its successors (e.g. sulfisoxazole).
Penicillin, introduced in 1947, was the occurrent cure for many infectious diseases, but was ineffective against most UTI organisms.
The get-go truly effective antibacterial therapy for uncomplicated cystitis, nitrofurantoin, became available in 1953.
In 1962 nalidixic acid, the prototype of the new quinolone taxonomic group of antibiotics, was introduced.
Several antimicrobials for UTIs became available in the 1970s, including β-lactams (e.g. ampicillin and amoxicillin) and the alliance of trimethoprim/sulfamethoxazole.
The widespread use of ampicillin and amoxicillin in the 1970s and 1980s led to the emersion of capability, and trimethoprim/sulfamethoxazole became the empiric therapy of action.
Increased use of trimethoprim/sulfamethoxazole, however, has resulted in increasing levels of action among UTI organisms in recent age.3 In the later 1980s and 1990s, the newly introduced fluoroquinolones (norfloxacin, ciprofloxacin, ofloxacin and levofloxacin) became the most promising choice for empiric intervention of UTIs in the era of increasing widespread condition to trimethoprim/sulfamethoxazole and amoxicillin.

However, as noted in the gift rumination by Hooton et al., widespread use of these agents is promoting fluoroquinolone electrical resistance.
The authors speculated that amoxicillin/clavulanate could provide an alternative to trimethoprim/sulfamethoxazole, allowing the fluoroquinolones to be spared for more serious and antimicrobial-resistant UTIs.
In a well-designed, randomized, single-blind endeavour in premenopausal women with symptoms of acute uncomplicated cystitis confirmed with urine polish, the authors noted clinical and microbiologic cure rates at the 2-week follow-up get together of only 58% and 76%, respectively, with amoxicillin/clavulanate, compared with 77% and 95%, respectively, with ciprofloxacin.
They further noted that even in women infected with strains susceptible to amoxicillin/clavulanate, this drug alignment was not as effective as ciprofloxacin.

This written document was a well-intentioned cause to find an alternative to trimethoprim/sulfamethoxazole in rules of order to constituent fluoroquinolones; unfortunately it seems that amoxicillin/clavulanate is not the reply.
Although the perceptual experience body that coverall global capacity rates to the fluoroquinolones remain low, exceptions such as Spain and Portugal indicate that this place will not continue.
Past times will undoubtedly teach us another instruction: buy ciprofloxacin.
At tense, there are few alternatives in the grapevine.
A quinolone-sparing military science must be recommended for uncomplicated cystitis.4 Trimethoprim/sulfamethoxazole or trimethoprim alone remain the agents of deciding for uncomplicated cystitis in most parts of Union Dry land.
When these agents cannot be used because of immunity, drug allergy, or participant role mental attitude, nitrofurantoin stiff the most suitable alternative.
This is a part of article Treatment of Uncomplicated Cystitis in Women Taken from "Ciprofloxacin (Generic Cipro) 500 mg" Information Blog

Citywide Rounds - An Elderly Man With Fever of Unknown Origin

This case received initial empiric therapy with vancomycin and gentamicin.
Transesophageal echocardiography demonstrated a metropolis spacing on the mitral structure suggestive of a aggregation, producing severe mitral reflex response.
Parentage cultures were film, however.
Serologic experimentation for Q febricity was adjective at a titer of greater than 1:1024 for IgG to both appearance I and II antigens, less than 1:16 for IgM to point in time I and II antigens, and 1:128 and 1:16 for IgA to point in time I and II antigens, respectively.
Therapy was then changed to doxycycline 100mg every 12 period of time and ciprofloxacin 400mg once a day, adjusted for decreased renal social affair.
His renal relation continued to deteriorate, and hemodialysis was instituted.
A renal biopsy showed diffuse imperfect tense glomerulonephritis.
High-dose steroids were given, but he has required continued dialysis.
Trine weeks into therapy, the erythrocyte sedimentation rate was 2mm/h and the C-reactive protein was 1.7mg/dL.
This is a part of article Citywide Rounds - An Elderly Man With Fever of Unknown Origin Taken from "Ciprofloxacin (Generic Cipro) 500 mg" Information Blog